Breaking AI & Tech News Analyzed

The Enhanced Games: A Doping-Filled Spectacle in Las Vegas I woke up in Las Vegas on Monday to an avalanche of messages from people across elite sport asking about the Enhanced Games. Some wanted to know what it was really like. Most, though, wanted to dance on its grave. So much for the organisers' promises that we would witness multiple world records. So much for their ridiculous claim to be the "Super Bowl of athletics, swimming and weightlifting!" Hubris meet nemesis. The Reality of Performance-Enhanced Competition Perhaps the most farcical moment came just before the women's 100m final. Only one athlete in the modest field had ever broken 11 seconds. But that didn't stop the announcer floating the idea that Florence Griffith Joyner's world record of 10.49sec might be under threat. "Are we going to witness history?" she asked. "Let's hope so." Of course we weren't. Tristan Evelyn, who was competing as a drug-free athlete, won in 11.26sec – a time that would have barely made it out of the first round of the 2024 Olympics. The Financial Temptation: Why Athletes Are Being Lured When I spoke to its chair, Christian Angermayer, on Sunday night he revealed the plan for next year was to invite fitness influencers to race alongside elite athletes. A legends section may also follow, he reckoned. Shortly afterwards, the Australian swim coach Brett Hawke revealed that his phone had been buzzing with elite stars wanting to sign up. Can you blame them? Hunter Armstrong competed clean and walked away with $250,000 (£186,000). That's 12½ times what gold at the World Aquatics championships pays. While World Athletics offers significantly more – the winner of each event in its Ultimate Championships will get $150,000 – Angermayer believes he can also lure big track stars over. The Cultural Divide: Puritans in Babylon Most of the time I felt like a puritan in Babylon. I didn't see the Michael Jackson lookalike, who has had plastic surgery to look uncannily like him and turned up at the aftershow party. But I did see dozens of fitness influencers going round filming each other, showing off their abs, and asking each other which protocol they were on. And hear predictions that there would be a pill that would give you all the benefits of easy exercise in zone 2. It felt like a trip to the Upside Down. The Marketing Machine: More Than Just a Sports Event Before I arrived in Vegas, I thought the Enhanced Games people were grifters. Now I think it is more accurate to say they are evangelicals. They truly believe these drugs have changed their lives. And they want others to enjoy them, albeit while burning a few hundred dollars a month. Some also believe that the Enhanced Games is a Trojan horse to sell drugs such as testosterone and human growth hormone. I don't quite agree. Because organisers are not exactly being shy here. The horse is rolling towards Troy draped in a large advert for testosterone cream and peptides. The Inevitable Collapse: Why the Enhanced Games Will Fail Ultimately, though, I believe the Enhanced Games will fail. Not next year. But probably over the next five. Why? Because while its movers and shakers are rich and smart, they don't come across as caring deeply about sport. They don't seem to understand its whims and irrationalities, its rivalries and narratives, its traditions and its heart. You can't pay a mortgage with morals, but you also can't build a lasting sporting movement on money alone.

The peptide-testing industry has seen a significant surge in demand, with laboratories testing thousands of unregulated substances claiming to support weight-loss and wellness. This growth is largely driven by the injectable peptide craze, with experts warning about the lack of reliable safety data and quality control.Peptides are short chains of amino acids, which can be found naturally in the body or made synthetically in laboratories. They include active ingredients in prescription weight-loss drugs, such as Wegovy, as well as experimental compounds pushed online by the booming biohacking and anti-ageing industries.Laboratories, such as Finnrick in Texas, have reported a substantial increase in testing requests, with around 60,000 samples processed annually, including roughly 2,000 orders from the UK since 2024. About a third of the products analysed failed basic quality checks, with issues including incorrect identity, purity, and quantity.Experts, including Dr. Luke Turnock and Peter Magic, have highlighted the risks associated with these unregulated substances, including potential long-term harms such as increased cancer risk and damage to organs. The large profit margins have also drawn nefarious actors into the supply chain.The UK is a significant market for peptides, with 2,000 testing orders since 2024, tied with Canada for third place globally. The Royal Pharmaceutical Society's Prof Amira Guirguis emphasized the need for oversight, traceability, and quality assurance in the peptide market.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

Robert F Kennedy Jr, the US health secretary, has unveiled a chaotic and unpredictable agenda for public health policy under his 'Make America Healthy Again' (Maha) initiative. His approach tends to favor personal choice and autonomy over large-scale, mandatory public health interventions, such as childhood vaccine requirements.The Maha agenda has raised concerns over the potential risks associated with injectable peptide drugs. Mr. Kennedy plans to open up the sale of 'about 14' of these drugs to the public, despite the US Food and Drug Administration (FDA) restricting 17 peptides in 2023 due to 'potential significant safety risks'. None of these peptides have been proven to be safe or effective for human use.The peptides in question are often promoted for biological enhancement, such as increasing muscle mass or cognitive benefits, but the evidence for these effects in humans is thin. Reports of people self-administering peptide therapies, usually bought from China 'for research use only', are widespread, particularly in Silicon Valley.The Maha project wants to make the grey market the only market, effectively sanctioning mass public use of unproven treatments. Peptides are clearly drugs and shouldn’t be allowed for widespread use without rigorous clinical trials. Opening loopholes for sale would undermine the precautionary principle that has successfully led public health policy for generations.It is also worth noting that other governments are unlikely to be as cavalier as Mr. Kennedy about peptides. However, people everywhere will continue to call for more personal choice and more bodily autonomy, and those conversations are important. The case for safety, proof, and regulation must be made to ensure that public health policy prioritizes the well-being of individuals.